Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
97
Views
20
CrossRef citations to date
0
Altmetric
Original Research

Inhibition of PCSK9 protects against radiation-induced damage of prostate cancer cells

Si-Shun GanDepartment of Urinary Surgery of Third Affiliated Hospital, Second Military Medical University, Shanghai, People’s Republic of China
,
Jian-Qing YeDepartment of Urinary Surgery of Third Affiliated Hospital, Second Military Medical University, Shanghai, People’s Republic of China
,
Lei WangDepartment of Urinary Surgery of Third Affiliated Hospital, Second Military Medical University, Shanghai, People’s Republic of China
,
Fa-Jun QuDepartment of Urinary Surgery of Third Affiliated Hospital, Second Military Medical University, Shanghai, People’s Republic of China
,
Chuan-Min ChuDepartment of Urinary Surgery of Third Affiliated Hospital, Second Military Medical University, Shanghai, People’s Republic of China
,
Yi-Jun TianDepartment of Urinary Surgery of Third Affiliated Hospital, Second Military Medical University, Shanghai, People’s Republic of China
,
Wei YangDepartment of Urinary Surgery of Third Affiliated Hospital, Second Military Medical University, Shanghai, People’s Republic of China
&
Xin-Gang CuiDepartment of Urinary Surgery of Third Affiliated Hospital, Second Military Medical University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 2139-2146 | Published online: 12 Apr 2017

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jing Hu, Meixia Zhang, Ling Gui, Qinsi Wan, Jiawei Zhong, Liangliang Bai & Mingyan He. (2022) PCSK9 Suppresses M2-Like Tumor-Associated Macrophage Polarization by Regulating the Secretion of OX40L from Hepatocellular Carcinoma Cells. Immunological Investigations 51:6, pages 1678-1693.
Read now

Articles from other publishers (19)

Palak P. Oza & Khosrow Kashfi. (2023) The evolving landscape of PCSK9 inhibition in cancer. European Journal of Pharmacology 949, pages 175721.
Crossref
Dandan An, Danyi Zhai, Chao Wan & Kunyu Yang. (2023) The role of lipid metabolism in cancer radioresistance. Clinical and Translational Oncology 25:8, pages 2332-2349.
Crossref
Si Fang, James Yarmolinsky, Dipender Gill, Caroline J. Bull, Claire M. Perks, George Davey Smith, Tom R. Gaunt & Tom G. Richardson. (2023) Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study. PLOS Medicine 20:1, pages e1003988.
Crossref
Yan Gu, Xiaozeng Lin, Ying Dong, Geoffrey Wood, Nabil G. Seidah, Geoff Werstuck, Pierre Major, Michael Bonert, Anil Kapoor & Damu Tang. (2023) PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity. Journal of Experimental & Clinical Cancer Research 42:1.
Crossref
Amita Singh, Pranesh Kumar, Archana Bharti Sonkar, Anurag Kumar Gautam, Abhishek Verma, Biswanath Maity, Himani Tiwari, Nanda Gopal Sahoo, Amit K. Keshari, S.K. Yadav & Sudipta Saha. (2023) A Comprehensive Review on PCSK9 as Mechanistic Target Approach in Cancer Therapy. Mini-Reviews in Medicinal Chemistry 23:1, pages 24-32.
Crossref
Tahlia Scheinberg, Blossom Mak, Lisa Butler, Luke Selth & Lisa G. Horvath. (2023) Targeting lipid metabolism in metastatic prostate cancer. Therapeutic Advances in Medical Oncology 15, pages 175883592311528.
Crossref
Malak Alannan, Nabil G. Seidah & Aksam J. Merched. (2022) PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity. Cells 11:24, pages 4132.
Crossref
Xiaotian Wang, Yongsheng Song, Yaxing Shi, Da Yang, Jiaxing Li & Bo Yin. (2022) SNHG3 could promote prostate cancer progression through reducing methionine dependence of PCa cells. Cellular & Molecular Biology Letters 27:1.
Crossref
Huimin Sun, Wen Meng, Jie Zhu & Lu Wang. (2022) Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition. Naunyn-Schmiedeberg's Archives of Pharmacology 395:6, pages 643-658.
Crossref
Aldo Bonaventura, Alessandra Vecchié, Massimiliano Ruscica, Francesco Grossi & Francesco Dentali. (2022) PCSK9 as a New Player in Cancer: New Opportunity or Red Herring?. Current Medicinal Chemistry 29:6, pages 960-969.
Crossref
Xiao-dan Xia, Zhong-sheng Peng, Hong-mei Gu, Maggie Wang, Gui-qing Wang & Da-wei Zhang. (2021) Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications. Frontiers in Cardiovascular Medicine 8.
Crossref
Khadijeh Mahboobnia, Matteo Pirro, Ettore Marini, Francesco Grignani, Evgeny E. Bezsonov, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2021) PCSK9 and cancer: Rethinking the link. Biomedicine & Pharmacotherapy 140, pages 111758.
Crossref
Anindita Bhattacharya, Abhirup Chowdhury, Koel Chaudhury & Praphulla Chandra Shukla. (2021) Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876:1, pages 188581.
Crossref
Umar Draz, Sana Yasin, Shafiq Hussain, Zaid Bin Faheem, Sarah Gul, Zanab Safdar, Mahmood Ahmad & Amjad Ali. (2021) Towards Investigating the Role of Proprotein Convertase Subtilisin/Kexin Family (PCSK/7/9) in Cancer by Using Bioinformatics Motif Detection Technique. Towards Investigating the Role of Proprotein Convertase Subtilisin/Kexin Family (PCSK/7/9) in Cancer by Using Bioinformatics Motif Detection Technique.
Tomas Koltai, Stephan J. Reshkin, Fátima Baltazar & Larry Fliegel. 2021. Prostate Cancer Metabolism. Prostate Cancer Metabolism 13 35 .
Arturo Cesaro, Vanessa Bianconi, Felice Gragnano, Elisabetta Moscarella, Fabio Fimiani, Emanuele Monda, Olga Scudiero, Giuseppe Limongelli, Matteo Pirro & Paolo Calabrò. (2020) Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term inhibition. BioFactors 46:3, pages 367-380.
Crossref
Junjie Chen, Liang Huang, Quan Zhu, Zhao Wang & Zhengyan Tang. (2019) MTSS1 hypermethylation is associated with prostate cancer progression . Journal of Cellular Physiology 235:3, pages 2687-2697.
Crossref
Hong TangZhixi WuYuan ZhangTingting XiaDong LiuJiarong CaiQingjian Ye. (2019) Identification and Function Analysis of a Five-Long Noncoding RNA Prognostic Signature for Endometrial Cancer Patients. DNA and Cell Biology 38:12, pages 1480-1498.
Crossref
Ming Sun, Donghua Geng, Shuqiang Li, Zhaofu Chen & Wenyan Zhao. (2018) LncRNA PART1 modulates toll-like receptor pathways to influence cell proliferation and apoptosis in prostate cancer cells. Biological Chemistry 399:4, pages 387-395.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.